GSGrace Julcit Shedul

Grace Julcit Shedul

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Grace Julcit Shedul has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Design and implementation of a drug revolving fund for hypertension treatment in primary care setting of the Federal Capital Territory, Nigeria

    by Grace Julcit Shedul, Eugenia N Ugwuneji, Erica L Jamro, Bolanle Banigbe, Patrick Ponzing, Inuwa Okpe, Nanna R Ripiye, Ikechukwu A Orji, Gabriel Lamkur Shedul, Samuel Osagie, et al.

    Background: Expanding treatment for hypertension requires ensuring access to affordable, high-quality blood pressure (BP) lowering medications. We describe the design, implementation and evaluation of a BP-lowering medication drug revolving fund (DRF) embedded in the Hypertension Treatment in Nigeria (HTN) Programme in 60 primary healthcare centres (PHCs) in the Federal Capital Territory, Nigeria. Methods: We used the exploration, preparation, implementation and sustainment framework to describe the DRF design and implementation and the reach, effectiveness, adoption, implementation and maintenance framework to report implementation outcomes. From June 2022 to December 2023, the DRF programme was implemented, and the data were collected from PHCs’ drug stock and finance records, quarterly DRF-supportive supervision visits and the HTN Programme. We performed descriptive statistics using complete case analysis and used an interrupted time-series design to explore temporal trends in the 3-month rolling average rate of BP-lowering prescriptions dispensed. Results: DRF design and implementation strategies included stakeholder engagement, leveraging the existing supply systems, developing medication and financial management protocols, training of site staff and DRF-supportive supervision visits, including joint problem solving. DRF was implemented in all 60 PHCs (100% reach). Adoption was high, with an increase in facilities selling DRF-supported medications from 80% to 100% (p value=0.01). Fidelity improved, including correct financial documentation (70%–100%; p value<0.0001) and stock cards (68%–94%; p value=0.0004). Effectiveness was high with low rates of medication stockouts of DRF-supported medications (1.7%–16%), with most medications at affordable prices, but a 12.1% drop in BP-lowering medications dispensing rate when the DRF replaced study-supplied free medication. Maintenance was high, with 100% of PHCs having a functional DRF after 1 year. Conclusion: A DRF programme to expand access to BP-lowering medications was implemented and effective in the Federal Capital Territory, Nigeria, and may serve as a model for other hypertension control programmes.


  • Open Access

    Implementation of Single-Pill Combination Medication for Hypertension Treatment by Nonphysician Health Care Workers at Primary Healthcare Facilities in Nigeria: An Explanatory Mixed Methods Study

    by Emmanuel I. Okpetu, Chisom Obiezu-Umeh, Boni M. Ale, Abigail S. Baldridge, Rosemary C. B. Okoli, Grace J. Shedul, Gabriel L. Shedul, Nanna R. Ripiye, Ikechukwu A. Orji, Lisa R. Hirschhorn, et al.

    Single-pill combination (SPC) therapy improves hypertension control; however, its implementation in primary care settings remains limited. In Nigeria, there is insufficient evidence on factors influencing SPC uptake, particularly from the perspective of healthcare workers (HCWs). This study examined the implementation of SPC medications for hypertension treatment by nonphysician HCWs at primary healthcare facilities (PHCs) in Nigeria. An explanatory sequential mixed methods study was conducted, building on a cluster randomized controlled trial embedded within the Hypertension Treatment in Nigeria Program. The trial compared SPC medications with free-equivalent combination therapies across 60 PHCs (January–June 2021). A subsequent qualitative component (September–December 2021) included two focus group discussions from 30 PHCs assigned to the SPC arm of the trial and five key informant interviews. The Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM) framework was used to assess implementation outcomes and identify facilitators and barriers. Integration of quantitative and qualitative findings was guided by the RE-AIM Qualitative Evaluation for Systematic Translation framework (QuEST). All 30 PHCs assigned to dispense SPCs adopted the medications (Reach/Adoption). Effectiveness: Blood pressure control (<140/90 mm Hg) was 54% (95% CI: 0.52, 0.56) in the SPC arm and 48% (95% CI: 0.46, 0.50) in the free-equivalent arm (cluster-adjusted p = 0.29). Monthly SPC use ranged from 21–37% across sites (Implementation), and 49% of patients remained in care at six months (Maintenance). Facilitators included training on SPC protocols, simplicity of dispensing the regimen, and perceived improvements in patient adherence. Challenges included SPC stockouts and concerns regarding nonphysician HCW capacity to manage complex cases. Policymakers identified the potential role of a Drug Revolving Fund (DRF) to support sustained SPC supply. The findings indicate favorable implementation outcomes associated with SPC use by nonphysician HCWs in PHCs. Addressing supply challenges, maintaining training, and providing supportive supervision may be important for sustaining SPC-based hypertension treatment.

  • Open Access

    An implementation trial to mAnage siCkle CELl disEase through incReased AdopTion of hydroxyurEa in Nigeria (ACCELERATE): Study protocol

    by Emmanuel Peprah, Joyce Gyamfi, John Patena, Hazal Kayalioglu, Tania Hameed, Gbenga Ogedegbe, Hyungrok Do, Dike Ojji, Deborah Adenikinju, Tayo Ajaye Oba, et al.

    Background: Despite the proven efficacy of evidence-based healthcare interventions in reducing adverse outcomes and mortality associated with Sickle Cell Disease (SCD), a vast majority of affected individuals in Africa remain deprived of such care. Hydroxyurea (HU) utilization among SCD patients in Sub-Saharan Africa (SSA) stands at less than 1%, while in Nigeria, approximately 13% of patients benefit from HU therapy. To enhance HU utilization, targeted implementation strategies addressing provider-level barriers are imperative. Existing evidence underscores the significance of addressing barriers such as inadequate healthcare worker training to improve HU adoption. The ACCELERATE study aims to evaluate the adoption of HU among providers through the Screen, Initiate, and Maintain (SIM) intervention, facilitated by healthcare worker training, clinical reminders, and task-sharing strategies, thereby enhancing patient-level SCD management in Nigeria. Methods: This study will implement the SIM intervention, encompassing patient screening, initiation of HU treatment, and maintenance of dosage, which will be implemented via the TAsk-Strengthening Strategy for Hemoglobinopathies (TASSH TCP), derived from our team’s TAsk-Strengthening Strategy for Hypertension control (TASSH) trials. Employing a sequential exploratory mixed-methods approach within the Exploration, Preparation, Implementation, and Sustainment (EPIS) framework, this study will assess SIM adoption by providers in Nigeria. The primary outcome is the rate of SIM adoption at clinical sites at 12 months, with secondary outcomes including sustainability/maintenance of SIM intervention and implementation fidelity. Discussion: This study’s findings will offer crucial insights into effective SCD management strategies, leveraging existing SCD clinical networks and resources in Nigeria to enhance HU adoption among providers in a scalable and sustainable manner. Additionally, the study will inform best practices for implementing HU therapy in resource-constrained settings, benefiting healthcare providers, policymakers, and stakeholders invested in improving SCD care delivery. Trial registration: NCT06318143.


  • Open Access

    Supportive supervision visits in a large community hypertension programme in Nigeria: implementation methods and outcomes

    by Gabriel Lamkur Shedul, Nanna Ripiye, Erica L Jamro, Ikechukwu A Orji, Grace Julcit Shedul, Eugenia N Ugwuneji, Emmanuel Okpetu, Boni M Ale, Samuel Osagie, Abigail S Baldridge, et al.

    Background: The Hypertension Treatment in Nigeria (HTN) Programme established a system for hypertension diagnosis and management in 60 public primary healthcare facilities in the Federal Capital Territory of Nigeria through the implementation of HEARTS, a multi-level strategy bundle including team-based care led by community health extension workers (CHEWs). To improve HEARTS implementation, supportive supervision was added as an implementation strategy in April 2020. Methods: A multidisciplinary supportive supervision team and data collection forms were developed and implemented at HTN-supported sites. Data from April 2020 to December 2023 from supportive supervision visits were used to measure supportive supervision implementation outcomes, including reach, fidelity, adoption and feasibility and effectiveness of quality of care, data reporting and facility readiness. Descriptive analyses were performed to summarise outcomes. Jonckheere-Terpstra or Cochran-Armitage trend test was used to measure change over time for medians or proportions, respectively. Results: The programme successfully designed and performed quarterly supportive supervision visits. There was high reach (100% sites with visits each year), fidelity (median 100% (IQR 89%–100%) of core components completed), adoption (100% teams provided quarterly visits) and increase in feasibility (planned visits completed) (90.8% to 97.8%, p=0.002). Effectiveness outcomes included an increase in patients with blood pressure (BP) checked in the last 3 days (78.4% to 84.4%, p=0.009), treatment cards without errors (71.5% to 85%. p<0.001), but a slight drop in CHEW fidelity to BP measurement technique (91.5% to 86.5%, p=0.02). Facility readiness increased in adequate staffing (56.7% to 98.3%, p<0.001), but decreased for equipment availability (98.3% to 90.0%, p=0.03). Overall, the proportion of facilities with all readiness components present increased from 0% to 63.3% (p<0.001). Conclusions: We designed and implemented a supportive supervision strategy with strong implementation outcomes and most effectiveness outcomes including facility readiness to provide quality hypertension care in Nigeria. This approach can be modelled for supporting HEARTS implementation in other settings. Trial registration number: The trial was prospectively registered at www.clinicaltrials.gov under NCT04158154 on 8 November 2019; https://clinicaltrials.gov/ct2/show/NCT04158154.


  • Open Access

    Effect of 3, 2-Drug Combinations of Antihypertensive Therapies on Blood Pressure Variability in Black African Patients: Secondary Analyses of the CREOLE Trial

    by Dike B. Ojji, Victoria Cornelius, Giles Partington, Veronica Francis, Shahiemah Pandie, Wynand Smythe, Nicky Hickman, Felix Barasa, Albertino Damasceno, Anastase Dzudie, et al.

    Background: The effect of 3 commonly recommended combinations of anti-hypertensive agents—amlodipine plus hydrochlorothiazide (calcium channel blocker [CCB]+thiazide), amlodipine plus perindopril (CCB+ACE [angiotensin-converting enzyme]-inhibitor), and perindopril plus hydrochlorothiazide (ACE-inhibitor+thiazide) on blood pressure variability (V) are unknown. Methods: We calculated the blood pressure variability (BPV) in 405 patients (130, 146, and 129 randomized to ACE-inhibitor+thiazide, CCB+thiazide, and CCB+ACE-inhibitor, respectively) who underwent ambulatory blood pressure monitoring after 6 months of treatment in the Comparisons of Three Combinations Therapies in Lowering Blood Pressure in Black Africans trial (CREOLE) of Black African patients. BPV was calculated using the SD of 30-minute interval values for 24-hour ambulatory BPs and for confirmation using the coefficient of variation. Linear mixed model regression was used to calculate mean differences in BPV between treatment arms. Within-clinic BPV was also calculated from the mean SD and coefficient of variation of 3 readings at clinic visits. Results: Baseline distributions of age, sex, and blood pressure parameters were similar across treatment groups. Participants were predominately male (62.2%) with mean age 50.4 years. Those taking CCB+thiazide had significantly reduced ambulatory systolic and diastolic BPV compared with those taking ACE-inhibitor+thiazide. The CCB+thiazide and CCB+ACE-inhibitor groups showed similar BPV. Similar patterns of BPV were apparent among groups using within-clinic blood pressures and when assessed by coefficient of variation. Conclusions: Compared with CCB-containing combinations, ACE-inhibitor plus thiazide was associated with higher levels, generally significant, of ambulatory and within-clinic systolic and diastolic BPV. These results supplement the differential ambulatory blood pressure–lowering effects of these therapies in the CREOLE trial.